Abstract
Background: The aim of the present interim analysis was to compare the clinical efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulphate (CHS) salt in patient groups eligible to receive clopidogrel.
Methods: A 2-arm, multicenter, open-label, phase 4 clinical trial. Consecutive patients (n=1,864) were screened and 1,800 were enrolled in the trial and randomized to CHS (n=759) or CB (n=798). Primary efficacy end point was the composite of myocardial infarction, stroke or death from vascular causes, and primary safety end point was rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria.
Results: At 6-months follow-up no differences were observed between CB and CHS in primary efficacy end point (OR, 0.80; 95% CI, 0.37 to 1.71; p=0.57). Rates of BARC-1,-2,-3a and -5b bleeding were similar between the two study groups whereas no bleeding events according to BARC-3b, -3c, -4 and -5a were observed in either CHS or CB group.
Conclusion: The clinical efficacy and safety of the generic CB is similar to that of the innovator CHS salt, thus, it can be routinely used in the secondary prevention of atherothrombotic events for a period of at least 6 months. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE study Clinical Trials.gov Identifier: NCT02126982).
Keywords: Acute coronary syndrome, clinical efficacy, clopidogrel besylate, coronary artery disease, generic clopidogrel, peripheral artery disease, stroke.
Current Vascular Pharmacology
Title:Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
Volume: 13 Issue: 6
Author(s): Kyriafina Terzoudi, Spiros Konstantinou, Haralampos Milionis, Adamantios Bourdakis, Dimitrios Nikolopoulos, Leonidas Peltekis, Nikos Prokopakis, Ioannis Sinteles, Christos S. Stroumbis, Nikolaos Kipouridis, Karmelos Tsilias, Ioannis Xaraktsis, Christos Charmpas, Georgios Hatziathanasiou, Zacharias Christogiannis, Demosthenes B. Panagiotakos, John A. Goudevenos, Alexandros D. Tselepis, Ioannis Giatrakos, Kalliroi I. Kalantzi, Maria E. Tsoumani, John N. Vakalis, Vasileios Vasilakopoulos, Konstantinos Vardakis, Konstantinos N. Vemmos, Maria Voukelatou, Georgios Giannakoulas, Ioannis V. Ntalas, Vasileios Giogiakas, Georgios Goumas, Nikos Dimoulis, Antonios Draganigos, Ioannis Efthimiadis, Maria Thoma and Evangelos Kazakos
Affiliation:
Keywords: Acute coronary syndrome, clinical efficacy, clopidogrel besylate, coronary artery disease, generic clopidogrel, peripheral artery disease, stroke.
Abstract: Background: The aim of the present interim analysis was to compare the clinical efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulphate (CHS) salt in patient groups eligible to receive clopidogrel.
Methods: A 2-arm, multicenter, open-label, phase 4 clinical trial. Consecutive patients (n=1,864) were screened and 1,800 were enrolled in the trial and randomized to CHS (n=759) or CB (n=798). Primary efficacy end point was the composite of myocardial infarction, stroke or death from vascular causes, and primary safety end point was rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria.
Results: At 6-months follow-up no differences were observed between CB and CHS in primary efficacy end point (OR, 0.80; 95% CI, 0.37 to 1.71; p=0.57). Rates of BARC-1,-2,-3a and -5b bleeding were similar between the two study groups whereas no bleeding events according to BARC-3b, -3c, -4 and -5a were observed in either CHS or CB group.
Conclusion: The clinical efficacy and safety of the generic CB is similar to that of the innovator CHS salt, thus, it can be routinely used in the secondary prevention of atherothrombotic events for a period of at least 6 months. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE study Clinical Trials.gov Identifier: NCT02126982).
Export Options
About this article
Cite this article as:
Terzoudi Kyriafina, Konstantinou Spiros, Milionis Haralampos, Bourdakis Adamantios, Nikolopoulos Dimitrios, Peltekis Leonidas, Prokopakis Nikos, Sinteles Ioannis, Stroumbis S. Christos, Kipouridis Nikolaos, Tsilias Karmelos, Xaraktsis Ioannis, Charmpas Christos, Hatziathanasiou Georgios, Christogiannis Zacharias, Panagiotakos B. Demosthenes, Goudevenos A. John, Tselepis D. Alexandros, Giatrakos Ioannis, Kalantzi I. Kalliroi, Tsoumani E. Maria, Vakalis N. John, Vasilakopoulos Vasileios, Vardakis Konstantinos, Vemmos N. Konstantinos, Voukelatou Maria, Giannakoulas Georgios, Ntalas V. Ioannis, Giogiakas Vasileios, Goumas Georgios, Dimoulis Nikos, Draganigos Antonios, Efthimiadis Ioannis, Thoma Maria and Kazakos Evangelos, Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial, Current Vascular Pharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570161113666150316220515
DOI https://dx.doi.org/10.2174/1570161113666150316220515 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 4
Current Medicinal Chemistry - Central Nervous System Agents Sildenafil and Cardioprotection
Current Pharmaceutical Design Roles of Mitogen-Activated Protein Kinases in the Regulation of CYP Genes
Current Drug Metabolism Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Editorial [Hot Topic:Anabolic Androgenic Steroids (AAS) as Doping Agents: Chemical Structures,Metabolism, Cellular Responses, Physiological and Pathological Effects (Guest Editor: V. Fineschi)]
Mini-Reviews in Medicinal Chemistry Chemoprevention of Lung Pathologies by Dietary n-3 Polyunsaturated Fatty Acids
Current Medicinal Chemistry Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Beta-arrestin Biased Agonism/Antagonism at Cardiovascular Seven Transmembrane-spanning Receptors
Current Pharmaceutical Design Secondary Prevention of Ischemic Stroke
Current Drug Targets Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) MicroRNAs in Peripheral Artery Disease
Current Topics in Medicinal Chemistry Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry The Gut Microbiota and Lipid Metabolism: Implications for Human Health and Coronary Heart Disease
Current Medicinal Chemistry Magnetic Field-Assisted Gene Delivery: Achievements and Therapeutic Potential
Current Gene Therapy Endothelin-1 and Human Platelets
Current Vascular Pharmacology Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Magnetomotive Molecular Nanoprobes
Current Medicinal Chemistry Isolation and Quantification of Chemical Marker of Polygonatum verticillatum: First Report
Current Traditional Medicine Hydrogels in Tissue Engineering: Scope and Applications
Current Pharmaceutical Biotechnology Anti-Inflammatory Therapy in Uveitis
Recent Patents on Inflammation & Allergy Drug Discovery